课题基金 / 基金详情

Characterization the disruption of mitochondrial function and induction of oxidative stress by SARS-CoV2

Characterization the disruption of mitochondrial function and induction of oxidative stress by SARS-CoV2
SARS-CoV2 对线粒体功能的破坏和氧化应激诱导的表征
批准号:
10640165
负责人:
Yidong Bai
金额:
$23.25万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-06-08 至 2024-05-31
关键词:
2019-nCoVA549ACE2ATP Synthesis PathwayAffectAgingAntioxidantsBindingBiogenesisBiologyCOVID-19COVID-19 impactCOVID-19 pathogenesisCOVID-19 patientCOVID-19 testCOVID-19 treatmentCell DeathCell LineCell modelCellsCompensationComplexDefectDiseaseElderlyElectron TransportEnergy MetabolismEngineeringEpithelial CellsEtiologyExhibitsFatigueGene ExpressionGenesGenomeHospitalizationHumanHypoxiaImmune responseInvadedInvestigationKnowledgeLaboratoriesLactate DehydrogenaseLeadLeber&aposs Hereditary Optic NeuropathyLentivirusMalignant NeoplasmsMeasuresMediatingMedicineMetabolicMetabolic DiseasesMetabolic syndromeMinority GroupsMitochondriaMitochondrial DNAMitochondrial DiseasesMitochondrial ProteinsModelingMolecular TargetMutationNADH dehydrogenase (ubiquinone)Neurodegenerative DisordersNuclearNuclear ImportOrganOxidative PhosphorylationOxidative StressOxidative Stress InductionPathogenicityPatientsPeptidesPhosphorylationPopulationProcessProductionProtein BiosynthesisProteinsProteomicsProtonsPublic HealthReactive Oxygen SpeciesReportingResearchResistanceRespiration DisordersRespiratory ChainRestSARS-CoV-2 genomeSARS-CoV-2 infectionSeriesSerumShortness of BreathSymptomsSyndromeSystemTestingTimeTranslationsViral ProteinsVirusVirus ReplicationYeastsaging populationalveolar epitheliumcommon symptomeffective therapyexperimental studyhigh riskinducible gene expressioninnovationinsightmitochondrial DNA mutationmitochondrial dysfunctionmutantnovelnovel strategiesoligomycin sensitivity-conferring proteinoxidative damageprematureprotein complexrespiratoryrespiratory proteinstable cell linesystematic review

项目摘要

项目成果

Yidong Bai的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1 Populations at higher risk of severe disease from COVID-19 are the elderly and those with metabolic 2 syndromes, the populations known for compromised mitochondrial function. In addition, the most common 3 symptoms in hospitalized COVID patients are shortness of breath and fatigue, indicating deficient oxygen and 4 energy metabolism, also suggesting defective mitochondria. COVID-19 patients also have significantly 5 elevated serum lactate dehydrogenase and increases oxidative stress, pointing to a possibility of reduced 6 mitochondrial oxidative phosphorylation (OXPHOS). Together, these information leads us to consider whether 7 mitochondrial dysfunction might contribute to the pathogenesis of COVID-19. A comprehensive proteomics 8 investigation and other studies identified at least 6 mitochondrially-localized SARS-CoV-2 viral proteins which 9 were shown to interact with host cell mitochondrial proteins involved in critical OXPHOS pathways converging 10 on respiratory Complex I biogenesis. Our lab has established expertise on the investigation of mitochondrial 11 biology and mitochondrial medicine, especially on Complex I-related OXPHOS biogenesis. Over the years we 12 have developed a series of unique cell models with different types of complex I defects, including sets of cells 13 with different contents of functional complex I subunits, a set cells with different complex I assembly capacity, 14 and a set of cells carrying pathogenic mutations in complex I subunit genes, as well as an engineered system 15 to rescue complex I-related function with the introduction of a yeast Complex I counterpart NDI1 gene. These 16 models exhibit different levels of complex I subunit expression, different capacities of complex I and overall 17 respiratory machinery assembly, and different complex I and overall mitochondrial OXPHOS activities. 18 Accordingly, these cell models also exhibit different sensitivities to oxidative stress and cell death. We have 19 also initiated a line of study on the effect of viruses on mitochondria and consequent implications on human 20 diseases. In addition, we have achieved to obtain 1.Inducible expression which could turn on and off the 21 SARS-CoV-2 proteins in our cell models at proper levels; 2.Multiple genes expression which can express 22 multiple SARS-CoV-2 proteins targeting one or multiple OXPHOS pathways simultaneously in our cell models; 23 3.Establishment of A549-hACE2 cell, where a human alveolar epithelial cell line, A549 was transduced with 24 lentiviruses expressing human ACE2. A549-hACE2 cells readily support SARS-CoV2 infection and replication; 25 4.Generated mutant SARS-CoV2 lines which could serve as controls. These provide a unique opportunity for 26 us to utilize our unique systems and expertise to fulfill with two independent and integrated aims to study the 27 interactions between SARS-CoV2 and mitochondria, and their implications on oxidative stress and cell death, 28 both in cell models with regulated mitochondrial function and in human alveolar epithelial cell line infected with 29 SARS-CoV2. We expect these research will help identify molecular targets of SARS-CoV2 proteins in host 30 cells and will also provide novel approaches for protecting against the harmful effects of COVID-19. 31 32
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The mitochondrial aspects of health disparity of hepatocellular carcinoma in Hispanic population
Characterization the disruption of mitochondrial function and induction of oxidative stress by SARS-CoV2
Characterization the disruption of mitochondrial function and induction of oxidative stress by SARS-CoV2
The role of Grp75 in supercomplex assembly and neurodegeneration
国内基金
海外基金
基于多重精准选择性碳氢官能化合成策略的抗A549/HepG2活性先导化合物发现及其作用靶标研究
  • 批准号:
    22007020
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    周志
  • 依托单位:
导向抗HepG2/A549先导化合物发现和结构优化的多重精准选择性C-H键官能化反应研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2019
  • 负责人:
    周志
  • 依托单位:
内蒙古白云鄂博稀土矿区大气可吸入颗粒物对A549细胞毒理研究
  • 批准号:
    81473017
  • 项目类别:
    面上项目
  • 资助金额:
    66.0万元
  • 批准年份:
    2014
  • 负责人:
    孙涓
  • 依托单位:
用于识别癌细胞A549的磁共振和荧光双功能探针的研究